Really

Scaling early Alzheimer’s detection with digital biomarkers.

Overview
Really detects, monitors, and assess daily function of individuals’, non-invasively and continuously over time to earlier detect and objectively measure preclinical symptoms of neuropsychiatric and neuropsychological disorders, from their everyday use of language, and other digital data sources.

Technology
Really integrates machine learning and computational neuroscience, to analyze longitudinal medical, behavioral, and contextual data derived from language, to provide a highly-scalable, low-friction, and cost-effective monitoring and assessment measure for brain health.
Really is a digital phenotypic / biomarker discovery and screening engine.

Applications
Research / Pharma / Universities
• Remote medical adherence
• Phenotypic candidate screening
• White paper data
• Planning and cost projection

Health Companies / Insurers
• White label B2C licenses

B2C
• Proactive health assistant

B2B
• Health management system

Contact
Carsten Jarfelt
Chief Business Officer
carsten.jarfelt@really.ai
+1 (650) 526-8121

Really Really, Inc.
950 Page Mill Rd,
Palo Alto, CA, USA
+1 (855) 242-6040

Profoundly human.

Our Mission
To make proactive and preventive healthcare universally accessible.

www.really.ai
How it works

**Digital Tools**
With the ubiquity of digital tools, consumers are generating ever increasing amounts of digital data.

**Consumer**
Consumers grant access to their data. Data exchange is opt-in, and consumers have full visibility and control.

**Really Engine**
The passive ingestion of objective data collected from digital tools is applied in a range of ways that can benefit the consumer.

**Technology applications**

- **Mycroft Partnership**
  - B2B / B2C Data Partnership
  - www.mycroft.ai

- **PreMD.**
  - Health Companies (Insurers)
  - www.premd.ai

- **PhenX.**
  - Research (Pharmaceuticals, Universities)
  - www.phenx.ai